NASDAQ · ARWR
Arrowhead Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ARWR: Nov 24, 2026
Arrowhead Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/24/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 9 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.59. The reported EPS for the same quarter last year was $-0.18.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.59 | $-0.35 | $-3.00 | 9 |
| Dec 2026 | $-1.23 | $-1.00 | $-1.42 | 3 |
| Mar 2027 | $-1.27 | $-0.87 | $-1.64 | 3 |
| Jun 2027 | $-1.24 | $-0.79 | $-1.65 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · The Motley Fool · Zacks- RTTNews · Oct 16, 10:55 AM EDTWeekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) – This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.
- MarketBeat · Oct 14, 7:02 PM EDTArrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT StudyWant Diversified Upside in Biotechnology? Check out LABUArrowhead Pharmaceuticals (NASDAQ:ARWR) presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system, alongside init
- RTTNews · Oct 14, 11:37 AM EDTArrowhead Reports Positive Phase 1/2a Data For Alzheimer's Candidate ARO-MAPT(RTTNews) – Arrowhead Pharmaceuticals, Inc. (ARWR) announced positive interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic for Alzheimer's disease and other tauopathies.
- MarketBeat · Sep 18, 8:02 PM EDTArrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch ProgressWant Diversified Upside in Biotechnology? Check out LABUArrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidat
- MarketBeat · Sep 18, 5:02 PM EDTArrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline ExpandsWant Diversified Upside in Biotechnology? Check out LABUArrowhead Pharmaceuticals (NASDAQ:ARWR) is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs
- The Motley Fool · Sep 6, 6:15 PM EDTArrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 MillionThe transaction was valued at $1 million.
- MarketBeat · Aug 31, 11:02 AM EDTArrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 TrialsWant Diversified Upside in Biotechnology? Check out LABUArrowhead Pharmaceuticals (NASDAQ:ARWR) presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycer
- The Motley Fool · Aug 14, 6:35 AM EDTIonis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?Q2 revenue fell, but last year included a large one-time payment.
- Zacks · Aug 6, 2:05 PM EDTSarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook UpdatedSRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
- MarketBeat · Aug 4, 6:03 PM EDTArrowhead Pharmaceuticals Q3 Earnings Call HighlightsWant Diversified Upside in Biotechnology? Check out LABUArrowhead Pharmaceuticals (NASDAQ:ARWR) reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and highlighting continued growth i
- RTTNews · Jul 27, 6:13 AM EDT5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%(RTTNews) – "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." – Warren Buffett. The Oracle of Omaha's timeless advice reminds us that patience is one of the key principles of investing.
- RTTNews · Jul 22, 11:09 PM EDTTop Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets(RTTNews) – Today's top gainers in the healthcare sector include Zhongchao, surging more than 190%; Lakewood-Amedex, advancing on positive antimicrobial drug progress; Arrowhead, delivering encouraging severe hypertriglyceridemia trial results; and LB Pharma, accelerating the LB-
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Arrowhead Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.